AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

METHODS FOR PREDICTING LIKELIHOOD OF RESPONDING TO TREATMENT IN PROSTATE CANCER

Technology Benefits

Prostate cancer

Technology Application

These novel biomarkers can help a medical professional evaluate a patient's medical record and assess multiple treatment strategies for clinical intervention of a patient's condition. A research professional can obtain a subject's biomarker information to advance research into ADT, ketoconazole, or abiraterone therapy or to evaluate the subject's enrollment, or continued participation in a research study or clinical trial.

Detailed Technology Description

This invention is based on the discovery that Single nucleotide polymorphisms (SNPs) in the SLC02B1 gene, alone or in combination with SNPs in the SLC01B3 gene, form a novel class of biomarkers that can predict the likelihood and duration of response of a patient undergoing prostate cancer treatment, including androgen deprivation therapy (ADT), ketoconazole therapy, or abiraterone therapy. The method includes providing a biological sample, such as a blood sample or a mucosal scraping sample of the lining of the mouth or a prostate tissue sample, which can be further fractionated, if desired, to a fraction containing particular cell types. Genomic DNA or mRNA can be isolated and the presence or absence of two or more of the SNP genotypes can be determined. The record can be created in a computer readable medium and compared with the data from a chip containing a panel of SNPs, indicating whether a subject contains SNPs associated with response to ADT, ketoconazole, or abiraterone therapy

Supplementary Information

Inventor: KANTOFF, Philip, W. | YANG, Ming | LEE, Gwo-Shu, Mary | SUN, Tong | XIE, Wanling
Priority Number: WO2011100503A1
IPC Current: C12Q000168
Assignee Applicant: Dana-Farber Cancer Institute Inc.
Title: METHODS FOR PREDICTING LIKELIHOOD OF RESPONDING TO TREATMENT | PROCÉDÉS POUR PRÉDIRE LA PROBABILITÉ DE RÉPONSE À UN TRAITEMENT
Usefulness: METHODS FOR PREDICTING LIKELIHOOD OF RESPONDING TO TREATMENT | PROCÉDÉS POUR PRÉDIRE LA PROBABILITÉ DE RÉPONSE À UN TRAITEMENT
Summary: The methods are used for predicting the likelihood of a subject having prostate cancer to respond to a treatment (claimed).
Novelty: Predicting likelihood of a subject having prostate cancer to respond to a treatment by detecting in a biological sample the presence or absence of two or more SCL02B1 single nucleotide polymorphism (SNP) genotypes

Industry

Disease Diagnostic/Treatment

Sub Group

Cancer/Tumor

Country/Region

USA

For more information, please click Here